A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB

Abroad (travel likely)Recruiting

Conditions

Ovarian Cancer Recurrent · Endometrial Cancer Recurrent · Cervical Cancer Recurrent

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat'sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Xiaolin Luo, phD) · luoxl@sysucc.org.cn · 15017599965
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center, Shenzhen, Guangdong, China
Contact: Study coordinator (Jingjing Wang)

Study leads

Jihong Liu, PhD
Principal Investigator
Sun Yat'sen University Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Ovary Neoplasm · Ovarian Cancer · Epithelial Ovarian Cancer

Abroad (travel likely)RecruitingPHASE1

Chapel Hill, United States

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Refractory Cancer · Recurrent Cancer · Solid Tumor, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Stanford, United States · Aurora, United States

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Metastatic Solid Tumor · Recurrent Solid Tumor · Advanced Solid Tumor

Abroad (travel likely)RecruitingPHASE1

Duarte, United States · La Jolla, United States

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

Cervical Cancer · Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Ji'nan, China